GSK/Valeant Potiga's Discontinuation Rate Could Be Its Undoing
Nearly one-third of clinical trial patients taking the antiepileptic had to stop due to adverse events.
Nearly one-third of clinical trial patients taking the antiepileptic had to stop due to adverse events.